Follow Payoneer to never miss an important update.
Kahn Swick & Foti is investigating the planned sale of the company to Nuvei for $7.40 per share. The firm is checking if the board of directors did enough to get the best possible price for shareholders or if the process was flawed. These types of investigations are common when a public company is being bought. They rarely stop a deal from happening, but they can sometimes lead to small settlements or more detailed disclosures about how the deal was reached. For now, this is a routine part of the merger process and does not change the core facts of the buyout.
Source: Business Wire
Payoneer grew its total transaction volume by 15 percent this quarter, reaching about 23.7 billion dollars. The standout was its business-to-business (B2B) segment, which grew 48 percent compared to last year. This is a key metric because these direct business payments are more profitable for Payoneer than the money it moves for large marketplaces like Amazon.
While the company reported a small net loss of about 2.4 million dollars, this was largely due to one-time costs. The underlying business remains healthy, with adjusted earnings, a measure that strips out those one-time merger costs, rising 7 percent. This performance happens against the backdrop of Payoneer's June agreement to be acquired by Nuvei, a deal that remains the primary focus for the company's future.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
Payoneer is scheduled to report its financial results this morning. Analysts expect the company to report revenue of about 270 million dollars and earnings of roughly 6 cents per share.
Beyond the headline numbers, we are watching the growth of business-to-business payments. This is the high-margin segment where Payoneer competes with traditional banks. We are also looking for stability in the take rate, which is the percentage of each transaction the company keeps as revenue. Maintaining this rate as the company grows is a key sign that its global regulatory network remains a competitive advantage.
The company has a mixed record of meeting analyst goals, but its underlying revenue has grown steadily even when it misses the quarterly profit target.
| Expectation | |
|---|---|
| EPS | $0.07 |
| Revenue | $286M |